Synaptogenix, Inc (OTC:SNPX) (formerly Neurotrope (NASDAQ:NTRP)) is a biopharmaceutical and diagnostics company structured around developing two product platforms: (1) diagnostic test for Alzheimer's Disease and (2) drug candidate called bryostatin for the treatment of Alzheime's Disease - both platform in the clinical testing stage. With the firm developing a new approach to combating AD and other neurodegenerative diseases, Neurotrope offers the potential to realize a paradigm shift to overcome one of today's most challenging clinical problems -- finding a way to slow or even prevent the progression of AD. In addition to the Company's Phase 2 trial of bryostatin-1 in advanced AD, Neurotrope has also conducted preclinical studies of bryostatin as a potential treatment for Fragile X Syndrome, Niemann-Pick Type C disease and Rett Syndrome -- three rare genetic diseases for which only symptomatic treatments are currently available. The FDA has granted Orphan Drug Designation to Neurotrope for Bryostatin-1 as a treatment for Fragile X Syndrome. Bryostatin-1 has already undergone testing in more than 1,500 people in cancer studies, thus creating a large safety data base that will further inform clinical trial designs in AD.
